

Gene name: **TNFSF10**

External Ids for TNFSF10 Gene: HGNC: [11925](#) NCBI Gene: [8743](#) Ensembl: [ENSG00000121858](#)

OMIM®: [603598](#) UniProtKB/Swiss-Prot: [P50591](#)

NCBI Gene Summary: The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein **preferentially induces apoptosis in transformed and tumor cells**, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. This protein binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis. The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

GeneCards Summary: TNFSF10 (TNF Superfamily Member 10) is a Protein Coding gene. Diseases associated with TNFSF10 include [Anaplastic Thyroid Carcinoma](#) and [Colon Adenocarcinoma](#). Among its related pathways are [MIF Mediated Glucocorticoid Regulation](#) and [Dimerization of procaspase-8](#). Gene Ontology (GO) annotations related to this gene include *signaling receptor binding* and *tumor necrosis factor receptor binding*. An important paralog of this gene is [TNFSF11](#).

UniProtKB/Swiss-Prot Summary: Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed:[10549288](#), [26457518](#)). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. ([TNF10_HUMAN,P50591](#))

Cellular localization: mainly extracellular and plasma membrane.

Full Name: *Tumor Necrosis Factor (Ligand) Superfamily Member 10*

Protein Name: **TRAIL** (TNF-Related Apoptosis-Inducing Ligand)

Protein Type:

- Cytokine
- Member of the **TNF superfamily** (similar to TNF- α and FasL)



Biological Function of TNFSF10 (TRAIL)

- TNFSF10 encodes TRAIL, a cytokine primarily involved in regulating apoptosis.
- Produced by:
 - Activated T cells
 - NK cells
 - Macrophages
 - Dendritic cells

- Key biological actions:
 - Induces apoptosis in target cells by binding death receptors (DR4/TRAIL-R1 and DR5/TRAIL-R2).
 - Maintains immune surveillance by eliminating infected, transformed, or damaged cells.
 - Modulates immune responses by influencing T cell proliferation, dendritic cell maturation, and NK cell activity.



How TNFSF10/TRAIL Works:

- Binds to death receptors (DR4 and DR5) on target cells.
- Triggers the extrinsic apoptotic pathway:
 - Recruitment of FADD (Fas-associated death domain).
 - Activation of Caspase-8, leading to downstream activation of Caspase-3 and apoptosis.
- Can also engage decoy receptors (DcR1 and DcR2) that do not signal apoptosis, regulating its activity.



Role of TNFSF10 in Sepsis

- In early sepsis:
 - TRAIL is upregulated as part of the innate immune response to eliminate infected or dysfunctional host cells.
- In late sepsis:
 - TRAIL-mediated apoptosis contributes to immune cell death, particularly T cell and dendritic cell apoptosis.
 - Leads to immune suppression, inability to clear infections, and increased risk of secondary infections.

● Excessive TRAIL activity is associated with the immunosuppressive phase of sepsis, where too many immune cells are lost.

- TRAIL can also affect:
 - Endothelial cells → promoting vascular dysfunction.
 - Parenchymal tissues → contributing to organ damage.



Clinical Relevance of TNFSF10 in Sepsis

Diagnostic Role:

- Plasma TRAIL levels rise during sepsis and systemic inflammatory conditions.
- Part of multi-marker panels distinguishing infectious sepsis from non-infectious inflammation.

Prognostic Role:

- High TRAIL levels correlate with:
 - More severe immune suppression.
 - Increased susceptibility to secondary infections.
 - Poorer recovery.
- Some studies show that decreased TRAIL activity is associated with better T cell survival and improved outcomes.

Therapeutic Interest:

- TRAIL inhibitors or modulation of death receptor signaling are considered potential strategies to preserve immune function in late sepsis.



Pathways Involving TNFSF10

- **Apoptosis pathway (KEGG hsa04210)** → activates extrinsic apoptosis via death receptors.
- **TNF signaling pathway (KEGG hsa04668)** → participates in inflammation and programmed cell death.
- **Immune system regulation** → especially in T cell apoptosis and immune homeostasis.




Supporting Literature

Doi: 10.4049/jimmunol.1101180

Doi: 10.1172/jci.insight.127143

Doi: 10.3390/jcm9061661



Enrichr-KG

